




The relative strengths and weaknesses of Kura Oncology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 156% points. The greatest weakness of Kura Oncology Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 377%, being 139% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	239,603
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,564
Liabilities, Non-Current	7,627
Other Assets	2,325
Other Compr. Net Income	462
Other Expenses	0
Other Liabilities	0
Other Net Income	4,339
Other Revenues	0
Property and Equipment	44
Research and Development	47,826
Selling, General and Administrative Expense	19,653

Output Variable	Value in 1000 USD
Assets	241,972
Liabilities	23,191
Expenses	67,479
Revenues	0
Stockholders Equity	218,781
Net Income	-63,140
Comprehensive Net Income	-62,909
BaseVar	168,722
ECR before LimitedLiability	312%
Economic Capital Ratio	377%